Frankfurt - Delayed Quote EUR

Spero Therapeutics, Inc. (2HA.F)

0.7640

-0.0060

(-0.83%)

As of 3:29:01 PM GMT+1. Market Open.

Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know

Spero Therapeutics (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 28 days ago

SPRO
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company’s Response to a Wells Notice from the SEC Relating to Certain Public Disclosures Made in 2022 Phase 3 PIVOT-PO Trial of Tebipenem HBr Reaches Over 60% Enrollment as of December 31, 2024; Remains on Track to Complete Enrollment in 2H 2025 Cash Balance and Cash Runway Guidance Remains into mid-2026 CAMBRIDGE, Mass., Jan. 10, 2025 (GL

GlobeNewswire last month

SPRO
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

The rally in ARQT's stock could be attributed to the encouraging regulatory updates seeking label expansion for its sole marketed drug.

Zacks last month

ARQT

CSTL

CTMX
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.

Zacks last month

CAPR

CSTL

SPRO
Neumora Stock Hits Record Low on Depression Drug Study Failure

NMRA stock falls after its experimental depression treatment failed to meet the primary and secondary endpoints in the first of three late-stage studies.

Zacks last month

NMRA

CSTL

SPRO
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study

Data from a mid-stage study show that treatment with Edgewise's experimental drug reduces levels of a biomarker related to skeletal muscle damage.

Zacks last month

EWTX

SPRO
Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Spero Therapeutics (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks last month

SPRO
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

Shares of QTTB fall after its experimental autoimmune disease drug failed to meet the primary endpoint in a mid-stage study for eczema.

Zacks 2 months ago

CSTL

SPRO

CTMX
JANX Stock Hits Record High on Prostate Cancer Study Data

An early-stage study data shows that treatment with Janux's JANX007 generates deep and durable efficacy responses in heavily pretreated patients with mCRPC.

Zacks 2 months ago

JANX

CSTL

SPRO
PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion.

Zacks 2 months ago

PTCT

NVS

SPRO
Grifols Stock Declines After Brookfield Drops Buyout Offer

Brookfield decides to drop its buyout offer for GRFS following discrepancies over the company's valuation.

Zacks 2 months ago

GRFS

BAM

SPRO
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.

Zacks 2 months ago

CTMX

SPRO

CSTL
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.

Zacks 2 months ago

GRFS

BAM

CTMX
FATE Presents Encourgaing Data From Lupus Study, Stock Gains

Fate Therapeutics presents promising data on FT819 showing the first patient treated experienced a favorable clinical experience, achieved drug-free clinical remission, and continues on-study.

Zacks 2 months ago

SPRO
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients.

Zacks 2 months ago

AZN

SPRO

CSTL
TenNor’s Phase III antibiotic trial meets all primary endpoints

The topline results found that rifasutenizol showed better safety and tolerability than the current standard of care.

Clinical Trials Arena 2 months ago

SPRO
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC

The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.

Zacks 2 months ago

JNJ

SPRO

CSTL
Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Spero Therapeutics ( NASDAQ:SPRO ) Third Quarter 2024 Results Key Financial Results Revenue: US$13.5m (down 47% from 3Q...

Simply Wall St. 2 months ago

SPRO
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates

Spero Therapeutics (SPRO) delivered earnings and revenue surprises of -18.52% and 41.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

SPRO

PHR
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter end

GlobeNewswire 2 months ago

SPRO

Performance Overview

Return	2HA.F	S&P 500
YTD	-21.07%	+3.06%
1-Year	-43.15%	+22.37%
3-Year	-91.22%	+37.18%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Spero Therapeutics, Inc. (2HA.F)

Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Neumora Stock Hits Record Low on Depression Drug Study Failure

EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study

Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

JANX Stock Hits Record High on Prostate Cancer Study Data

PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

Grifols Stock Declines After Brookfield Drops Buyout Offer

JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

FATE Presents Encourgaing Data From Lupus Study, Stock Gains

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

TenNor’s Phase III antibiotic trial meets all primary endpoints

CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC

Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

Performance Overview